Home›Trial›NCT04106219
🔬NCT04106219Phase 1ACTIVE NOT RECRUITING

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Study Summary

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

Conditions
Neuroblastoma
Interventions / Drugs
LY3295668 ErbumineTopotecanCyclophosphamide
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment71 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.866751+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.